Stock AnalizBIO-TECHNE Corp TECH
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
BIO-TECHNE Corp (TECH) is a healthcare company listed in the US with a market value of about $11.4B. In the twelve months to September 30, 2026 it had revenue of $1.2B and net income of $172M, a net margin of 14.0%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 66.8, a price to free cash flow of 37.1, 5-year revenue growth of 5% a year, a 5-year average ROIC of 8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.
Score: 2.6 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.2B | $1.2B | $1.1B | $1.1B | $931M | $739M | $714M | $643M | — |
| Net income | $172M | $182M | $73M | $168M | $285M | $272M | $140M | $229M | $96M | $126M | $49M |
| Free cash flow | $308M | $263M | $257M | $236M | $216M | $280M | $308M | $153M | $156M | $149M | — |
| EPS (diluted) | $1.09 | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.46 | $0.62 | $0.83 | — |
| Net margin | 14.0% | 15.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.6% | — |
| ROIC | — | 7.9% | 2.8% | 6.7% | 10.4% | 12.8% | 11.3% | 7.2% | 7.5% | 7.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $70.50, 3% below the current price; targets range from $50.00 to $73.00; the consensus rating is “Hold”; expected EPS is $2.03 for the fiscal year ending June 30, 2027.
Frequently asked questions
What is BIO-TECHNE’s P/E ratio?
About 66.8, based on the last twelve months of diluted earnings per share (forward P/E about 33.4).
Is BIO-TECHNE stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does BIO-TECHNE pay a dividend?
Yes. The dividend yield is about 0.44%, and it has paid dividends for 9 years in our data.
Is BIO-TECHNE a good stock to buy?
We do not give buy or sell advice. BIO-TECHNE scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.